Every material Form 8-K Scinai Immunotherapeutics Ltd. has filed with the SEC since May 04, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On June 4, 2023, BiondVax Pharmaceuticals Ltd., which trades as SCNI, entered an exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) from Max-Planck-Innovation GmbH and University Medical Center Gottingen. The company agreed to issue 17,000 American Depository Shares to the counterparties and to owe milestone payments and royalties on net sales, and the license will terminate if an IND is not submitted by the stated deadlines.
17,000 American Depository Shares to be issued to the counterparties within 45 days of June 4, 2023
Recipients agreed not to sell the ADSs until June 4, 2024
IND submission deadline of June 30, 2025, with a possible extension of 12 months per EUR 500,000 payment
License terminates prior to December 31, 2026 if the IND deadline is not met
Director George Lowell resigned from the board of directors effective May 12, 2023, after serving since 2008. The filing states he did not resign over any disagreement with the company, and he will remain on the Scientific Advisory Board as a liaison between that board and the Board. The filing names the registrant as BiondVax Pharmaceuticals Ltd.; the company and Mr. Lowell are still negotiating his compensation for the new roles.
Mr. Lowell submitted his board resignation on May 10, 2023, effective May 12, 2023
He had served as a Board member since 2008; the Board chairman, Mark Germain, thanked him for 15 years of service
Mr. Lowell will stay on the Scientific Advisory Board and become a liaison between it and the Board
Compensation for his continuing and new roles is still under discussion
BiondVax Pharmaceuticals Ltd., which the filing identifies as the registrant for Scinai (SCNI), received a Nasdaq letter on May 1, 2023 saying it does not meet the $2,500,000 minimum stockholders' equity requirement for the Nasdaq Capital Market. The company reported a stockholders' deficit of $1,760,000 in its 2022 annual report, and the notice has no immediate effect on its ADSs, which continue to trade as BVXV.
Nasdaq letter dated May 1, 2023 cites the $2,500,000 minimum stockholders' equity requirement under Listing Rule 5550(b)(1).
Stockholders' deficit of $1,760,000 reported in the 10-K for the year ended December 31, 2022, filed April 17, 2023.
Compliance plan due to Nasdaq by June 15, 2023; if accepted, Nasdaq may grant 180 calendar days to regain compliance.
The company does not currently meet Nasdaq's alternative standards for market value of listed securities or net income from continuing operations.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Scinai Immunotherapeutics Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →